TRDA Q4 2025 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-96.5% YoY

Gross Profit

$413,00031.8% margin

Operating Income

-$42M-3249.3% margin

Net Income

-$39M-3014.9% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

-19.5%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$377M

Total Liabilities

$71M

Stockholders' Equity

$306M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$37M	-96.5%
Gross Profit	$413,000	$37M	-98.9%
Operating Income	-$42M	-$6M	-619.4%
Net Income	-$39M	$1M	-3562.8%